Last reviewed · How we verify
SCB-2019 with AS03 adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
SCB-2019 with AS03 adjuvant (SCB-2019 with AS03 adjuvant) — Clover Biopharmaceuticals AUS Pty.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SCB-2019 with AS03 adjuvant TARGET | SCB-2019 with AS03 adjuvant | Clover Biopharmaceuticals AUS Pty | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SCB-2019 with AS03 adjuvant CI watch — RSS
- SCB-2019 with AS03 adjuvant CI watch — Atom
- SCB-2019 with AS03 adjuvant CI watch — JSON
- SCB-2019 with AS03 adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). SCB-2019 with AS03 adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/scb-2019-with-as03-adjuvant. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab